Main navigation
Search Results
-
EU-wide networking of innovation ecosystems for personalised healthcare https://www.bio-pro.de/en/projects/current-projects/preciseu-personalised-medicine-empowerment-connecting-innovation-ecosystems-across-europe -
The start of a transnational cooperation for a future of sustainable healthcare - 25/07/2024 BIOPRO is a sustainability partner in the EU HACK-IT-NET project
The HACK-IT-NET (“Health And Care Knowledge and Innovation Transfer NETwork”) project aims to provide holistic and seamless healthcare for all patients in the Alpine region. The project, which was launched in July 2024 and will run for three years, aims to bring together stakeholders in the healthcare sector to create a forward-looking healthcare ecosystem in the Alpine region. BIOPRO is a partner.
https://www.bio-pro.de/en/information/press-release/biopro-sustainability-partner-eu-hack-it-net-project -
Event - DIS&CO Health | Market opportunities in Morocco
Online , Registration deadline: Informationsveranstaltunghttps://www.gesundheitsindustrie-bw.de/en/event/dis-und-co-health-marktchancen-marokko -
Event - DIS&CO Health | Market opportunities in Morocco
Online , Registration deadline: Informationsveranstaltunghttps://www.bio-pro.de/en/events/dis-und-co-health-marktchancen-marokko -
Research association - 24/07/2024 SPI-MP: pioneer in personalised medical technology
Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.
https://www.gesundheitsindustrie-bw.de/en/article/news/spi-mp-pioneer-personalised-medical-technology -
Event - - Trinational HealthTech Days 2024
Breisach am Rheinhttps://www.gesundheitsindustrie-bw.de/en/event/trinational-healthtech-days-2024 -
Event - - MEDigIT 2024
Lille, France, Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/medigit-2024 -
Press release - 11/07/2024 Presentation of the DKFZ Innovation Award and DKFZ Patient Expert Award
The "Friends of the German Cancer Research Center" association supports the DKFZ and aims to help strengthen its position in international competition. With the DKFZ Innovation Award presented at this year's DKFZ annual reception, the association honored Titus Brinker as a researcher whose highly innovative work builds a bridge from research to practical application with commercialization potential.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/presentation-dkfz-innovation-award-and-dkfz-patient-expert-award -
Save the date - Meet & Match - Gender Medicine: Biological insights and healthcare advances
Strasbourg (France) | CIARUS, Registration deadline: Meet & Matchhttps://www.gesundheitsindustrie-bw.de/en/event/meet-und-match-gender-medicine-biological-insights-and-healthcare-advances -
Save the date - Meet & Match - Gender Medicine: Biological insights and healthcare advances
Strasbourg (France) | CIARUS, Registration deadline: Meet & Matchhttps://www.bio-pro.de/en/events/meet-und-match-gender-medicine-biological-insights-and-healthcare-advances -
-
Press release - 10/07/2024 HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration -
TWYCE GmbH - 10/07/2024 Better immune response against prostate cancer thanks to new bispecific antibodies
TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.
https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies -
Press release - 09/07/2024 Unique characteristics of previously unexplored protein discovered
Freiburg-Prague research collaboration achieves scientific breakthrough in understanding cell division. The international research collaboration has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/unique-characteristics-previously-unexplored-protein-discovered -
Press release - 05/07/2024 Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy
The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy -
Press release - 05/07/2024 The Symphony of Organelles
With "OrgaPlexing", scientists at the MPI of Immunobiology and Epigenetics have developed a new method that shows how guardian cells of the immune system, the macrophages, orchestrate their cell structures during inflammation or bacterial infection, making it possible to observe the interactions between several organelles simultaneously and thus providing insights into cell metabolism and the production of inflammatory molecules.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/symphony-organelles -
Press release - 04/07/2024 Antibody can improve immune cell therapy against leukemia
Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia -
Event - - MedFit 2024
Lille, France, Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/medfit-2024 -
Event - - BioFIT 2024
Lille, Frankreich, Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/biofit-2024 -
Press release - 03/07/2024 Max Planck scientists develop cost-efficient medical imaging method
Max Planck scientists will present a low-field magnetic resonance imaging (MRI) scanner in Lindau. Two researchers from the MPI for Biological Cybernetics in Tübingen, Germany, will present a model of a new low-field MRI system. It combines hyperpolarization with imaging techniques that can be run at low magnetic field strengths. The quality of the MRI images can be enhanced with the help of artificial intelligence.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/max-planck-scientists-develop-cost-efficient-medical-imaging-method -
Press release - 03/07/2024 Advancement Award for Heidelberg Molecular Biologist
For her ground-breaking scientific studies in the field of synthetic biology, the 2024 Alfried Krupp Advancement Award is to go to Prof. Dr Kerstin Göpfrich. The award, endowed with one million euros in funding, is granted annually by the Alfried Krupp von Bohlen und Halbach Foundation to young academics holding their first professorship in the natural and engineering sciences.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/advancement-award-heidelberg-molecular-biologist -
Press release - 03/07/2024 CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-initiates-strategic-restructuring-align-resources-focus-high-value-mrna-pipeline-opportunities -
Press release - 02/07/2024 Artificial intelligence helps physicians make precise heart diagnoses
Researchers from the University of Heidelberg have published a study on more than 60,000 patients in the renowned journal Lancet Digital Health, demonstrating the potential of AI in cardiac medicine.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-intelligence-helps-physicians-make-precise-heart-diagnoses -
Press release - 02/07/2024 Faster use of new technologies in rehabilitation
BioRegio STERN Management GmbH is a partner in the new RehAllianCE project, which is being funded by the EU as part of the Interreg CENTRAL EUROPE program. The focus is on the use of new technologies in rehabilitation to improve patient care. The aim is to increase the innovation capacities of SMEs so that aids such as rehabilitation robots, exoskeletons etc. can be used more quickly.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/faster-use-new-technologies-rehabilitation -
Press release - 02/07/2024 DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier
Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-spin-epignostix-raises-euro-43m-seed-round-commercialize-diagnostic-tumor-classifier